12:00 AM
Nov 19, 2012
 |  BC Week In Review  |  Clinical News  |  Clinical Results

MK-5172: Interim Phase II data

Interim data from both cohorts of a double-blind Phase II trial in 332 treatment-naïve patients with chronic HCV genotype 1 infection showed that 82.8-93% of patients receiving once-daily 100, 200, 400 or 800 mg MK-5172 plus standard of care (SOC; peginterferon alfa-2b and ribavirin) for 12 weeks achieved a cEVR, the primary endpoint, vs. 74.2% of patients who received SOC for 4 weeks followed by the addition of boceprevir. In the first cohort of 136 patients, 96.2% of patients...

Read the full 375 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >